Randomized phase II trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC).

被引：0
|
作者：
Rolski, J.
Ramlau, R.
Dediu, M.
Russo, M. W.
Ross, G. A.
Mather, R. A.
Bandekar, R. R.
Grunberg, S. M.
机构：
[1] Oncol Ctr, Krakow, Poland
[2] Reg Lung Dis Ctr, Poznan, Poland
[3] Inst Oncol, Bucharest, Romania
[4] GlaxoSmithKline Inc, Collegeville, PA USA
[5] Univ Vermont, Burlington, VT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8513
引用
收藏
页码：471S / 471S
页数：1
相关论文
共 50 条
  • [41] Impact of gender on the efficacy of the neurokinin-1 antagonist casopitant mesylate in cinv with moderately emetogenic chemotherapy (MEC): Subgroup analysis from a randomized, double- blind, placebo-controlled phase II trial
    Arpornwirat, Wichit
    Albert, Istvan
    Hansen, Vincent L.
    Russo, Mark W.
    Witman, Philip A.
    Bandekar, Rajesh R.
    ANNALS OF ONCOLOGY, 2006, 17 : 302 - 302
  • [42] Incidence of chemotherapy-induced nausea and vomiting after highly and moderately emetogenic chemotherapy in the era of NK-1 receptor antagonists. Perception versus reality
    Majem, M.
    Moreno, E.
    Perez, J.
    Calvo, N.
    Feliu, A.
    Gich, I.
    Tibau, A.
    Mangues, M. A.
    Barnadas, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy.
    Boccia, Ralph V.
    Cooper, William
    O'Boyle, Erin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Impact on patients' daily life activities of NEPA, the oral fixed-dose combination of netupitant, a new NK1 receptor antagonist (RA), and palonosetron (PALO) plus dexamethasone (DEX) versus PALO plus DEX for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)
    Aapro, Matti S.
    Rossi, Giorgia
    Rizzi, Giada
    Borroni, Maria Elisa
    Nagl, Norman G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31)
  • [45] Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis
    Di Maio, M.
    Baratelli, C.
    Bironzo, P.
    Vignani, F.
    Bria, E.
    Sperti, E.
    Marcato, M.
    Roila, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] Generic Netupitant Plus Palonosetron and Dexamethasone for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Retrospective Study
    Simhadri, Soumya
    Dayyala, Sowmya
    Musinipally, Anjani Devi
    Guram, Lavanya
    Madavi, Mamatha
    Kancha, Ramakrishna
    Puligundla, Krishna Chaitanya
    SOUTH ASIAN JOURNAL OF CANCER, 2024,
  • [47] Phase III study of APF530 versus ondansetron with a neurokinin 1 antagonist plus corticosteroid in preventing highly emetogenic chemotherapy-induced nausea and vomiting: MAGIC trial.
    Schnadig, Ian D.
    Agajanian, Richy
    Dakhil, Shaker R.
    Gabrail, Nashat Y.
    Smith, Robert E.
    Taylor, Charles W.
    Wilks, Sharon
    Cooper, William
    Mosier, Michael
    Payne, Yvette
    Klepper, Michael
    Vacirca, Jeffrey L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [48] A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
    Aapro, M. S.
    Grunberg, S. M.
    Manikhas, G. M.
    Olivares, G.
    Suarez, T.
    Tjulandin, S. A.
    Bertoli, L. F.
    Yunus, F.
    Morrica, B.
    Lordick, F.
    Macciocchi, A.
    ANNALS OF ONCOLOGY, 2006, 17 (09) : 1441 - 1449
  • [49] THE EFFICACY OF TRIPLET ANTIEMETIC THERAPY FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN LUNG CANCER PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY: PALONOSETRON (PALO), APREPITANT (APR), AND DEXAMETHASONE (DEX)
    Yoshizawa, H.
    Sato, K.
    Makino, M.
    Kobayashi, O.
    Tanaka, H.
    Miura, S.
    Watanabe, S.
    Tanaka, J.
    Kagamu, H.
    Ichiei, N.
    ANNALS OF ONCOLOGY, 2012, 23 : 509 - 509
  • [50] Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy
    Hesketh, Paul J.
    Schnadig, Ian D.
    Schwartzberg, Lee S.
    Modiano, Manuel R.
    Jordan, Karin
    Arora, Sujata
    Powers, Dan
    Aapro, Matti
    CANCER, 2016, 122 (15) : 2418 - 2425
12345